Abstracts

Type I IFN Signaling and Regulation in Vesatolimod-Treated Virally Suppressed Adults With HIV-1

Background: Vesatolimod (VES) is a well tolerated and selective toll-like receptor-7 agonist under development as part of an HIV cure regimen. VES treatment increases interferon-stimulated gene (ISG) expression and immune cell activation in people with HIV (PWH); additionally, VES monotherapy promotes a modest delay in HIV rebound in HIV controllers, and VES pharmacodynamic response is…

Lower ADCC After 26 Weeks of PEG-IFN-α2b and 2 bNAbs in Otherwise Suppressed HIV-1+

Background: Previous studies suggested that pegylated interferon α2b (peg-IFN-α2b) and the broadly neutralizing antibodies (bNabs) 3BNC117 and 10-1074 may contribute to cure-related strategies. We evaluated the effect of a 26-week immunotherapy course with peg-IFN-α2b+bNAbs in the cytotoxic function and activation of natural killer (NK) cell subsets in persons with HIV infection (PWH) that participated in…

Strong Latency Reversal by C. megalobotrys Extract in ART-Suppressed PBMC and Humanized Mice

Background: Latency reversing agents (LRAs) have had limited success in vivo, indicating a need for more potent agents. ‘Mukungulu,’ an extract prepared from the bark of Croton megalobotrys and traditionally used for HIV/AIDS management in Northern Botswana (Africa), is an LRA in latent HIV cell lines and contains protein kinase C-activating phorbol esters (PMID: 28970153).…

IRF5 Mediates Persistent Inflammatory Responses in HIV-1–Infected Macrophages

Background: People living with HIV (PWH) experience chronic inflammation, which can contribute to HIV-associated co-morbidities. Long-lived HIV-1-infected macrophages are important mediators of chronic innate immune activation. Additive effects of aging and persistent HIV-1 infection can promote macrophage dysfunction, contributing to chronic inflammation, or ‘inflammaging’. We previously reported that nuclear export and cytoplasmic expression of HIV-1…

Immunological Non-Responders Have CD4+ Immunosenescense and Impaired Lymphocyte Cytokine Production

Background: Immunological non-responders (INRs) are people living with HIV (PLHIV) that fail to restore CD4+ T-cell counts despite suppressive antiretroviral therapy (ART). INRs are at a higher risk for non-HIV related mortality and morbidity, such as non-aids malignancies. IL-2 induced CD4+ T-cell count increases did not effect clinical endpoints in previous trials, indicating a persistent…

Phenotype of Gamma-Delta T-Cells in Acute HIV-1 Infection Predict Neutralization Breadth

Background: New HIV vaccine approaches are focused on eliciting broadly neutralizing antibodies (bNABs). Leveraging the U.S. Military HIV Research Program’s (MHRP) therapy naïve RV217 cohort comprised of study participants monitored for HIV acquisition and progression, we have previously shown that B cell engagement and activation within the first 14-43 days of viremia are predictive of…

Immune Responses Associated With Mpox Viral Clearance in People With and Without HIV Coinfection

Background: During the emergence of the global mpox outbreak in May 2022, over 90,000 cases were diagnosed, disproportionately affecting those living with HIV. Milder re-infections have been recently reported. Here, we extensively characterized cellular and humoral responses in people without HIV (PWoH) and with HIV (PWH) at acute mpox, determined their impact on disease severity…